Skip to main content

Viatris Inc Value Stock - Dividend - Research Selection

Viatris

ISIN: US92556V1061 , WKN: A2QAME

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Where is Viatris Inc. (VTRS) Headed According to the Street?

2026-02-10
Viatris Inc. (NASDAQ:VTRS) is one of the best healthcare stocks under $50 to invest in. Viatris Inc. (NASDAQ:VTRS) received a rating update from Piper Sandler on January 28, which adjusted the price target on the stock to $12 from $9 while maintaining a Neutral rating on the shares. The rating update came ahead of the […]

Why Viatris (VTRS) Stock Is Up Today

2026-02-09
Shares of medication company Viatris (NASDAQ:VTRS) jumped 6.4% in the afternoon session after investment bank UBS upgraded the company's stock from "Neutral" to "Buy" and increased its price target.

Uncover the latest developments among S&P500 stocks in today's session.

2026-02-09
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

Monday's pre-market session: top gainers and losers in the S&P500 index

2026-02-09
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.

A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment

2026-02-07
Viatris (VTRS) is back in focus after the company named veteran pharma lawyer Matthew J. Maletta as its new Chief Legal Officer, succeeding long serving executive Brian Roman during a planned transition. See our latest analysis for Viatris. The appointment of a seasoned Chief Legal Officer comes at a time when momentum in Viatris' share price has been building, with a 30 day share price return of 17.01%, a 90 day share price return of 44.07%, and a 1 year total shareholder return of 42.78%...

Women Are One Patch Away From Menopause Relief—if Only They Could Find It

2026-02-07
Manufacturers and pharmacies are buckling under demand for estradiol patches used to treat symptoms of menopause and perimenopause.

3 Unprofitable Stocks with Questionable Fundamentals

2026-02-04
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

2026-02-03
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

2026-02-03
Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 20

Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q4 2025 Update

2026-02-02
Davis Selected Advisers’ Q4 2025 13F: $22.25B portfolio, top holding concentration, biggest adds/cuts & key stock moves—get the latest update now.